secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2023-01-11T23:59:59+00:00
Accession:  0001193125-23-006489
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin estimates FY2022 total revenue of $2.09B, VOXZOGO sales $169M
----------------------------------------------------------------------

- Preliminary unaudited total revenue for FY2022 estimated at $2.09 billion.
- VOXZOGO contributed approximately $169 million in revenue for FY2022.
- Revenue figures are preliminary and subject to completion of quarterly closing procedures.
- Full FY2022 results expected to be reported in February 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000119312523006489/0001193125-23-006489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000119312523006489/d405652d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-006489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer